The pathological feature of granular corneal dystrophy type 2 (GCD2) is that mutant TGF-β deposits on the cornea with the defect of autophagy degradation in corneal fibroblasts, and TFEB has therapeutic potential in alleviating this situation to treat the disease [84]. This evidence concerns the gene TGFB1 and granular corneal dystrophy type II.